Aug 28, 2025
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 06, 2025
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jun 25, 2025
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Apr 30, 2025
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Mar 08, 2025
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Feb 26, 2025
Q32 Bio to Participate in Upcoming March Investor Conferences
Feb 10, 2025
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Feb 04, 2025
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Dec 10, 2024
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
Nov 07, 2024
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oct 14, 2024
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024
Aug 29, 2024
Q32 Bio to Participate in Upcoming September Investor Conferences
Aug 08, 2024
Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 09, 2024
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
Jul 01, 2024
Q32 Bio Joins Russell 3000® Index
May 09, 2024
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Apr 03, 2024
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
Mar 25, 2024
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Feb 21, 2024
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases